The earnings call was overwhelmingly positive, highlighting significant sales growth across all products, increased revenue guidance, strong financial performance, and successful market expansion strategies. While there was a minor reevaluation in patient responder data, it did not significantly detract from the overall positive performance and outlook for the company.

Company Guidance

During the second quarter of 2025, Rigel Pharmaceuticals demonstrated substantial progress, achieving net product sales of over $58 million, marking a 76% increase year-over-year, and total revenues of $101.7 million, including $42.7 million from contract collaborations. The company recognized $40 million in noncash revenue from their collaboration with Lilly, contributing to a net income of $59.6 million and an increased cash balance of $108.4 million. Rigel's updated financial guidance for 2025 projects total revenues between $270 million and $280 million, with net product sales of $210 million to $220 million, reflecting anticipated growth of 45% to 52% compared to 2024. The growth trajectory was attributed to demand across Rigel's commercial products, TAVALISSE, GAVRETO, and REZLIDHIA, and improved patient affordability due to policy changes. The company also emphasized continued financial discipline and strategic development of their hematology and oncology pipeline, including the Phase 1b study of R289 and the exploration of olutasidenib's potential in IDH1 mutated cancers.

Record Net Product Sales

Achieved net product sales of more than $58 million in Q2 2025, marking a 76% year-over-year increase and the company's best quarter ever.

Significant Revenue Growth and Updated Guidance

Total revenue for Q2 2025 was $101.7 million. The company raised its total revenue guidance for 2025 to $270-$280 million, up from $200-$210 million, reflecting anticipated growth of 45% to 52% compared to 2024.

Strong Performance of Commercial Products

TAVALISSE reported $40.1 million in net product sales, a 52% increase year-over-year. GAVRETO generated $11.8 million, and REZLIDHIA $7 million, marking a significant increase for all products.

Successful Financial Management

Rigel generated $59.6 million in net income and increased its cash balance to over $108 million in Q2 2025.

Expansion of Global Market Access

TAVALISSE is now commercially available in Japan, Europe, Canada, Israel, and South Korea, expanding its global footprint.

Rigel (RIGL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

RIGL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	0.90 / -	0.7	―	―	―
Aug 05, 2025	2025 (Q2)	2.58 / 3.28	-0.06	5566.67% (+3.34)
May 06, 2025	2025 (Q1)	0.09 / 0.63	-0.5	226.00% (+1.13)
Mar 04, 2025	2024 (Q4)	0.45 / 0.80	0	―
Nov 07, 2024	2024 (Q3)	0.06 / 0.70	-0.3	333.33% (+1.00)
Aug 06, 2024	2024 (Q2)	-0.29 / -0.06	-0.4	85.00% (+0.34)
May 07, 2024	2024 (Q1)	-0.29 / -0.50	-0.8	37.50% (+0.30)
Mar 05, 2024	2023 (Q4)	-0.20 / 0.00	0.1	―
Nov 07, 2023	2023 (Q3)	-0.71 / -0.30	-1.1	72.73% (+0.80)
Aug 01, 2023	2023 (Q2)	-0.78 / -0.40	-0.8	50.00% (+0.40)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

RIGL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$24.24	$29.81	+22.98%
May 06, 2025	$18.26	$18.47	+1.15%
Mar 04, 2025	$22.08	$20.29	-8.11%
Nov 07, 2024	$15.44	$22.07	+42.94%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Rigel (RIGL) report earnings?

Rigel (RIGL) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).

What is Rigel (RIGL) earnings time?

Rigel (RIGL) earnings time is at Nov 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is RIGL EPS forecast?

RIGL EPS forecast for the fiscal quarter 2025 (Q3) is 0.9.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing